Revelation Biosciences, Inc.
REVBHealthcare|Biotechnology|US
$3.89
+0.33 (+9.27%)
DCF Value
$106.03
Tangible Book / Share
$12.93
Cash / Share
$16.30
Financials
Financial Snapshot
Market Cap
$2.2M
Enterprise Value
-$6.1M
Revenue (TTM)
$0.00
Net Income (TTM)
-$12.2M
Cash & Investments
$9.1M
Net Cash
$8.3M
Free Cash Flow (TTM)
-$10.2M
Operating CF (TTM)
-$10.1M
Debt/Equity
0.11
Cash Runway & Burn Rate
Cash on Hand
$9.1M
Quarterly Burn
$2.5M
Monthly Burn
$841.7K
Est. Runway
~3.6 quarters
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $0.00 | $537.0K | $1.3M | $5.3M | $12.0M | $6.5M | $10.7M | $9.1M | |
| Operating Cash Flow | $0.00 | -$215.1K | -$11.1M | -$11.2M | -$7.3M | -$18.3M | -$8.3M | -$10.1M | |
| Free Cash Flow | $0.00 | -$215.1K | -$11.2M | -$11.2M | -$7.3M | -$18.3M | -$8.3M | -$10.2M | |
| Capital Expenditure | $0.00 | $4.00 | -$132.0K | $0.00 | $0.00 | -$19.2K | $0.00 | -$111.5K | |
| Financing Cash Flow | $0.00 | $74.3M | $8.0M | $15.2M | $14.0M | $12.8M | $12.5M | $6.6M |
R&D Spending
R&D (TTM)
$5.8M
R&D Intensity
—
R&D Growth vs Prior
+42.0%
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $0.00 | $2.6M | $6.9M | $5.4M | $4.1M | $3.5M | $4.1M | $5.8M | |
| SG&A | $3.6K | $1.2M | $5.0M | $5.5M | $4.5M | $4.4M | $5.0M | $6.9M |
Income Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $40.0K | $25.0K | $27.9K | $27.1K | $13.1K | |
| Gross Profit | $0.00 | $0.00 | $0.00 | -$40.0K | -$25.0K | -$27.9K | -$27.1K | -$13.1K | |
| R&D | $0.00 | $2.6M | $6.9M | $5.4M | $4.1M | $3.5M | $4.1M | $5.8M | |
| SG&A | $3.6K | $1.2M | $5.0M | $5.5M | $4.5M | $4.4M | $5.0M | $6.9M | |
| Operating Income | -$3.6K | -$3.8M | -$12.0M | -$10.9M | -$8.7M | -$8.0M | -$9.1M | -$12.7M | |
| Interest Expense | $0.00 | $0.00 | $41.8K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$3.6K | -$3.8M | -$12.0M | -$10.8M | -$120.3K | -$15.0M | -$8.9M | -$12.2M | |
| Net Income | -$3.6K | -$1.6M | -$12.0M | -$10.8M | -$120.3K | -$15.0M | -$8.9M | -$12.2M | |
| EPS (Diluted) | -47.04 | -63228.83 | -142800.00 | -67503.59 | -58.87 | -613.76 | -167.65 | -42.53 | |
| EBITDA | -$3.6K | $0.00 | -$11.9M | -$10.8M | -$8.6M | -$7.9M | -$9.0M | -$12.3M | |
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.09 | 0.56 |
Balance Sheet
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $0.00 | $11.7K | $1.3M | $5.3M | $12.0M | $6.5M | $10.7M | $9.1M | |
| Short-Term Investments | $0.00 | $525.3K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $0.00 | $651.3K | $1.9M | $5.4M | $12.1M | $6.6M | $10.8M | $9.3M | |
| Total Assets | $22.7K | $74.2M | $2.0M | $5.5M | $12.2M | $6.6M | $11.6M | $10.0M | |
| Total Current Liabilities | $26.3K | $3.4M | $2.1M | $4.5M | $5.6M | $1.9M | $2.0M | $2.3M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $460.8K | |
| Total Liabilities | $26.3K | $6.3M | $2.1M | $4.5M | $5.6M | $1.9M | $2.7M | $2.8M | |
| Stockholders' Equity | -$3.6K | $67.8M | -$99.5K | $1.1M | $6.6M | $4.7M | $8.9M | $7.2M | |
| Retained Earnings | -$3.6K | -$5.7M | -$14.5M | -$25.3M | -$25.5M | -$40.5M | -$49.4M | -$59.1M |
Cash Flow Statement
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $0.00 | -$215.1K | -$11.1M | -$11.2M | -$7.3M | -$18.3M | -$8.3M | -$10.1M | |
| Capital Expenditure | $0.00 | $4.00 | -$132.0K | $0.00 | $0.00 | -$19.2K | $0.00 | -$111.5K | |
| Free Cash Flow | $0.00 | -$215.1K | -$11.2M | -$11.2M | -$7.3M | -$18.3M | -$8.3M | -$10.2M | |
| Investing Cash Flow | $0.00 | -$74.0M | -$132.0K | $0.00 | $0.00 | -$19.2K | $0.00 | -$111.5K | |
| Financing Cash Flow | $0.00 | $74.3M | $8.0M | $15.2M | $14.0M | $12.8M | $12.5M | $6.6M | |
| Issuance of Stock | -$10.0K | $74.2M | $600.0K | $4.5M | $14.0M | $12.8M | $12.5M | $6.6M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $15.0K | $0.00 | -$796.9K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $43.8K | $470.9K | $301.1K | $155.7K | $168.8K | $595.4K | $1.7M | |
| Net Change in Cash | $0.00 | $11.7K | -$3.2M | $4.0M | $6.7M | -$5.5M | $4.2M | -$3.6M |
Dilution Tracker
Shares outstanding grew 341000.0% over 5 years — significant dilution
Shares Outstanding
1M
5-Year Share Growth
+341000.0%
Stock Issuance (TTM)
$6.6M
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.09 | 0.56 | |
| Change vs Prior % | — | -66.2% | 223.1% | 90.5% | 1175.6% | 1100.4% | 262.0% | 531.0% | |
| Stock Issuance | -$10.0K | $74.2M | $600.0K | $4.5M | $14.0M | $12.8M | $12.5M | $6.6M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $43.8K | $470.9K | $301.1K | $155.7K | $168.8K | $595.4K | $1.7M |
Margins & Profitability
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| ROE % | 100.0% | -2.4% | 12050.7% | -1029.0% | -1.8% | -319.4% | -100.6% | -124.2% | |
| ROA % | -16.0% | -2.2% | -587.0% | -196.8% | -1.0% | -227.1% | -77.0% | -121.3% | |
| ROIC % | 100.0% | -5.4% | 14447.3% | -1046.3% | -130.2% | -169.4% | -94.4% | -158.1% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | 37.4% | -11.5% | 3.1% | |
| Operating Income | 0.0% | -104238.1% | -214.8% | 9.1% | 20.3% | 7.9% | -13.7% | |
| Net Income | 0.0% | -44718.6% | -635.2% | 9.7% | 98.9% | -12405.6% | 40.7% | |
| EPS (Diluted) | 0.0% | -134315.0% | -125.8% | 52.7% | 99.9% | -942.6% | 72.7% | |
| Operating Cash Flow | 0.0% | 0.0% | -5056.6% | -1.2% | 35.1% | -151.4% | 54.9% | |
| Free Cash Flow | 0.0% | 0.0% | -5118.1% | 0.0% | 35.1% | -151.7% | 54.9% | |
| R&D Expense | 0.0% | 0.0% | 170.0% | -22.2% | -22.9% | -14.4% | 14.5% | |
| SG&A Expense | 0.0% | 33840.9% | 307.8% | 9.0% | -17.8% | -1.9% | 13.1% | |
| Total Assets | 0.0% | 327023.7% | -97.2% | 169.5% | 121.9% | -45.8% | 74.9% | |
| Book Value / Share | 0.0% | 5520812.8% | -100.0% | 655.5% | -50.5% | -94.1% | -48.0% | |
| Debt | 0.0% | 0.0% | 0.0% | -100.0% | 0.0% | 0.0% | 0.0% | |
| Diluted Shares | 0.0% | -66.2% | 223.1% | 90.5% | 1175.6% | 1100.4% | 262.0% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B0.30
10Y Low / Med / High0.22 / 3.22 / 40.78
EV/EBITDA0.49
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$106.03
Tangible Book / Share
$12.93
Net Current Assets / Share
$11.39
Graham Net-Net
$11.32
Cash / Share
$16.30
| Metric | Trend | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -97600.00 | -74.77 | -33.60 | -3.97 | -342.93 | -1.01 | -0.13 | -0.09 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -97172.90 | 1.81 | -4051.86 | 40.78 | 6.20 | 3.22 | 0.22 | 0.30 | |
| EV/EBITDA | -97172.90 | 0.00 | -33.67 | -3.48 | -3.38 | -1.09 | 0.88 | 0.49 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-11.02
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $49.0M | $2.3M | $25.4M |
| Net Income | -$3.2M | -$1.8M | -$2.1M |
| EPS | $-36.30 | $-20.23 | $-23.59 |
| # Analysts (EPS) | 2 | 2 | 1 |